Moderna (MRNA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Moderna (MRNA)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Key Insights
Critical company metrics and information
Share Price
$44.44Market Cap
$17.10 BillionTotal Outstanding Shares
384.82 Million SharesTotal Employees
5,600Dividend
No dividendIPO Date
December 7, 2018SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.modernatx.com
Historical Stock Splits
If you bought 1 share of MRNA before July 22, 2010, you'd have 0.00 shares today.
Execution Date | Split Amount |
---|---|
August 3, 2017 | 1-for-10 (Reverse Split) |
December 23, 2011 | 1-for-10 (Reverse Split) |
July 22, 2010 | 1-for-4 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow | $-1.31 Billion |
Net Cash Flow From Investing Activities | $1.95 Billion |
Net Cash Flow From Operating Activities, Continuing | $-3.21 Billion |
Net Cash Flow From Operating Activities | $-3.21 Billion |
Net Cash Flow From Financing Activities, Continuing | $-50.00 Million |
Net Cash Flow From Investing Activities, Continuing | $1.95 Billion |
Net Cash Flow, Continuing | $-1.31 Billion |
Net Cash Flow From Financing Activities | $-50.00 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Earnings Per Share | $5.82 |
Operating Expenses | $6.12 Billion |
Diluted Average Shares | $782.00 Million |
Revenues | $5.08 Billion |
Income/Loss From Equity Method Investments | $-62.00 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Income/Loss From Continuing Operations After Tax | $-2.22 Billion |
Net Income/Loss | $-2.22 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Other Operating Expenses | $1.29 Billion |
Net Income/Loss Attributable To Parent | $-2.22 Billion |
Benefits Costs and Expenses | $7.43 Billion |
Research and Development | $4.83 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $-2.22 Billion |
Costs And Expenses | $7.77 Billion |
Income Tax Expense/Benefit | $-129.00 Million |
Income/Loss Before Equity Method Investments | $-2.29 Billion |
Cost Of Revenue | $1.65 Billion |
Gross Profit | $3.43 Billion |
Operating Income/Loss | $-2.69 Billion |
Basic Average Shares | $768.00 Million |
Income/Loss From Continuing Operations Before Tax | $-2.35 Billion |
Basic Earnings Per Share | $5.82 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Parent | $11.93 Billion |
Equity | $11.93 Billion |
Inventory | $412.00 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Wages | $244.00 Million |
Other Current Liabilities | $1.58 Billion |
Assets | $15.80 Billion |
Accounts Payable | $373.00 Million |
Liabilities And Equity | $15.80 Billion |
Other Current Assets | $9.25 Billion |
Noncurrent Liabilities | $1.68 Billion |
Current Liabilities | $2.20 Billion |
Liabilities | $3.88 Billion |
Current Assets | $9.67 Billion |
Noncurrent Assets | $6.14 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Moderna (MRNA)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.